ROIV
Roivant Sciences Ltd.Company Information
- Company Name
- Roivant Sciences Ltd.
- CIK
- CIK0001635088
- Category
- Large accelerated filer
- Ticker: Exchange
- ROIV: Nasdaq
- Fiscal Year End
- March 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ROIV
SEC filing data through
Insider Sentiment
- Last purchase
- 2025-09-18
- Last sale
- 2026-09-15
- Shares purchased (TTM)
- 3,315
- Shares sold (TTM)
- 17,677,135
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 551,955,722
- Shares outstanding
- 720,776,739
- Ownership
- 76.58%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- -1.17%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 1,248 | 1,419 | 1,478 | 1,237 | 1,238 | 2,715 | 1,991 | 1,959 | 5,679 | 6,495 | 6,671 | 1,408 | ||||||
| Marketable Securities Current | 2,594 | 2,873 | 3,052 | 3,149 | 3,265 | 2,171 | 3,156 | 3,428 | - | 0 | - | - | ||||||
| Assets Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | 0 | 0 | 320 | - | 156 | - | - | ||||||
| Other Assets Current | 128 | 105 | 130 | 126 | 113 | 113 | 217 | 94 | 323 | 81 | 136 | 143 | ||||||
| Assets Current | 4,742 | 5,167 | 4,660 | 4,512 | 4,616 | 5,000 | 5,364 | 5,801 | 6,001 | 6,732 | 6,807 | 1,552 | ||||||
| Property Plant And Equipment Net | 11 | 12 | 13 | 26 | 15 | 12 | 14 | 14 | 18 | 15 | 22 | 24 | ||||||
| Operating Lease Right Of Use Asset | 79 | 80 | 84 | 85 | 87 | 89 | 91 | 43 | 45 | 44 | 47 | 49 | ||||||
| Investments Fair Value Disclosure | 445 | 408 | 434 | 412 | 284 | 303 | 290 | 311 | 263 | 248 | 240 | 250 | ||||||
| Intangible Assets Net Excluding Goodwill | - | - | - | - | - | - | - | - | 136 | 138 | 150 | 141 | ||||||
| Other Assets Noncurrent | 30 | 41 | 35 | 28 | 31 | 33 | 34 | 37 | 33 | 38 | 47 | 50 | ||||||
| Disposal Group Including Discontinued Operation Assets Noncurrent | - | - | - | - | - | 0 | 0 | 0 | - | 146 | - | - | ||||||
| Assets | 5,306 | 5,709 | 5,225 | 5,063 | 5,033 | 5,437 | 5,792 | 6,206 | 6,496 | 7,222 | 7,313 | 2,066 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 25 | 18 | 13 | 15 | 12 | 24 | 24 | 25 | 28 | 14 | 35 | 44 | ||||||
| Accrued Liabilities Current | 169 | 206 | 118 | 108 | 89 | 114 | 104 | 111 | 138 | 119 | 122 | 153 | ||||||
| Operating Lease Liability Current | 12 | 11 | 10 | 9 | 9 | 10 | 10 | 10 | 9 | 9 | 10 | 11 | ||||||
| Long Term Debt Current | - | - | - | - | - | - | - | - | 12 | 12 | 46 | 49 | ||||||
| Taxes Payable Current | 74 | 46 | - | - | - | 0 | - | - | - | - | - | - | ||||||
| Other Liabilities Current | 3 | 1 | 10 | 1 | 4 | 1 | 4 | 9 | 28 | 14 | 31 | 9 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Current | - | - | - | - | - | 0 | 0 | 401 | - | 110 | - | - | ||||||
| Liabilities Current | 284 | 281 | 152 | 134 | 114 | 149 | 141 | 556 | 215 | 267 | 245 | 266 | ||||||
| Operating Lease Liability Noncurrent | 95 | 96 | 99 | 90 | 90 | 90 | 90 | 43 | 46 | 45 | 47 | 49 | ||||||
| Long Term Debt | - | - | - | - | - | - | - | - | 312 | 431 | 403 | 389 | ||||||
| Other Liabilities Noncurrent | 6 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 2 | 2 | 4 | 5 | ||||||
| Liabilities Of Disposal Group Including Discontinued Operation Noncurrent | - | - | - | - | - | 0 | 0 | 0 | - | 434 | - | - | ||||||
| Liabilities | 385 | 416 | 251 | 257 | 217 | 250 | 256 | 626 | 601 | 774 | 728 | 740 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 5,131 | 5,025 | 4,944 | 4,772 | 4,644 | 4,562 | 4,721 | 4,775 | 4,782 | 5,396 | 5,390 | 5,321 | ||||||
| Retained Earnings Accumulated Deficit | -900 | -502 | -695 | -429 | -316 | 116 | 460 | 396 | 671 | 576 | 727 | -4,369 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 1 | 4 | 21 | 20 | 17 | 9 | 8 | -18 | -18 | -4 | -28 | -3 | ||||||
| Stockholders Equity | 4,922 | 4,527 | 4,269 | 4,805 | 4,816 | 4,688 | 5,536 | 5,580 | 5,895 | 5,969 | 6,585 | 949 | ||||||
| Minority Interest | 691 | 765 | 705 | 443 | 470 | 500 | 346 | 427 | 460 | 480 | 495 | 377 | ||||||
| Liabilities And Stockholders Equity | 5,306 | 5,709 | 5,225 | 5,063 | 5,033 | 5,437 | 5,792 | 6,206 | 6,496 | 7,222 | 7,313 | 2,066 | ||||||
| Shortterm Debt Fair Value | - | - | - | - | - | - | - | - | 6 | 6 | 27 | 28 | ||||||
| Long Term Debt Fair Value | - | - | - | - | - | - | - | - | 82 | 204 | 195 | 189 | ||||||
| Available For Sale Securities Debt Securities | - | - | - | 2,789 | 1,803 | - | - | - | - | - | - | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | 7,000 | ||||||
| Common Stock Shares Issued | 723 | 720 | 710 | 690 | 682 | 696 | 720 | 733 | 739 | 807 | 805 | 801 | ||||||
| Shares Outstanding | 723 | 720 | 710 | 690 | 682 | 696 | 720 | 733 | 739 | 807 | 805 | 801 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialRoivant Sciences Ltd. (ROIV) — SEC Financial Statements & Analysis
Roivant Sciences Ltd. (ROIV) is a pharmaceutical preparations company, incorporated in D0. Roivant Sciences Ltd. trades on Nasdaq as: ROIV. Roivant Sciences Ltd. (ROIV)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Roivant Sciences Ltd. carries a market cap of $25.51B, a P/E ratio of -61.52x, a P/B ratio of 5.18x, a P/S ratio of 3386.66x, an enterprise value of $24.26B, and an EV/EBITDA multiple of -40.89x. On profitability, it posts a gross margin of -105.80%, an operating margin of -7914.75%, a net margin of -5504.54%, a Return on Equity (ROE) of -8.52%, a Return on Assets (ROA) of -8.02%, and a Return on Invested Capital (ROIC) of -16.44%. Per share, it reports EPS of $-0.58, diluted EPS of $-0.58, free cash flow per share of $-1.15, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -67.58% year-over-year, net income growth of -39.75% year-over-year, and EPS growth of -43.13% year-over-year. On the balance sheet, it maintains a current ratio of 16.72x, a quick ratio of 16.72x, working capital of $4.46B, a debt-to-equity ratio of 0.08x, a debt ratio of 0.07, an interest coverage ratio of -74.88x, free cash flow of $-830.93M (TTM), and net debt of $-1.25B. Figures sourced from SEC EDGAR.
- Market Cap
- $25.51B
- P/E TTM
- -61.52x
- EPS TTM
- $-0.58
- P/B TTM
- 5.18x
- ROE TTM
- -8.52%
- ROA TTM
- -8.02%
- Debt To Equity
- 0.08x
- Free Cash Flow TTM
- $-830.93M
- Net Revenue TTM Growth 1Y
- -67.58%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Roivant Sciences Ltd. in?
Roivant Sciences Ltd. (ROIV) operates in the Pharmaceutical Preparations industry.
What exchange does ROIV trade on?
Roivant Sciences Ltd. (ROIV) trades on the Nasdaq.
Where is Roivant Sciences Ltd. incorporated?
Roivant Sciences Ltd. is incorporated in Bermuda.
When was Roivant Sciences Ltd. (ROIV)'s most recent SEC filing?
Roivant Sciences Ltd. (ROIV)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is ROIV's market cap?
Roivant Sciences Ltd. (ROIV) has a market capitalization of $25.51B as of 2026-06-30.
What is ROIV's EPS (earnings per share)?
Roivant Sciences Ltd. (ROIV)'s trailing twelve month EPS is $-0.58 as of 2026-06-30.
What is ROIV's ROE (return on equity)?
Roivant Sciences Ltd. (ROIV)'s trailing twelve month Return on Equity (ROE) is -8.52% as of 2026-06-30.
What is ROIV's ROA (return on assets)?
Roivant Sciences Ltd. (ROIV)'s trailing twelve month Return on Assets (ROA) is -8.02% as of 2026-06-30.
What is ROIV's ROIC (return on invested capital)?
Roivant Sciences Ltd. (ROIV)'s trailing twelve month Return on Invested Capital (ROIC) is -16.44% as of 2026-06-30.
What is ROIV's EV/EBITDA?
Roivant Sciences Ltd. (ROIV)'s trailing twelve month EV/EBITDA is -40.89x as of 2026-06-30.